Events › 2014
Didier Pruneau, CSO of GenSight, featured at Gene Therapy (Dec. 3-4, 2014,Brussels) and gave a talk on "Translational development of GS010, an ocular mitochondrial gene therapy".
GenSight presented at Therapeutic Area Partnership, in Boston (MA), as Top projects to watch in track #6 Advanced Therapies on Thursday 20, 2.15-2.30 pm.
GenSight Biologics attended BIO, San Diego, CA, USA.
GenSight Biologics presented in the the Next wave Companies list at BioEquity, Amsterdam, the Netherlands.
GenSight Biologics attended ARVO annual meeting, Orlando, FL, USA and presented a poster:Safety, local tolerability and biodistribution of GS010 (AAV2/2-ND4), a gene therapy medicinal product in development for Leber Hereditary Optic Neuropathy (LHON), Physiology/Pharmacology, 342 Gene Therapy and Delivery, Poster Number: 3340 - B0280.
GenSight Biologics presented at BioEurope Spring.
GenSight Biologics expands its Series A round to the French seed fund for innovative biotherapies and rare diseases.
Read the full press release (available only in French)
GenSight Biologics attended JP Morgan Healthcare Conference and Biotech Showcase, San Francisco, CA, USA.